Literature DB >> 25293717

Somatic neurofibromatosis type 1 (NF1) inactivation events in cutaneous neurofibromas of a single NF1 patient.

Denise Emmerich1, Tomasz Zemojtel2, Jochen Hecht3, Peter Krawitz4, Malte Spielmann4, Jirko Kühnisch1, Karolina Kobus4, Monika Osswald4, Verena Heinrich5, Peter Berlien6, Ute Müller6, Victor-F Mautner7, Katharina Wimmer8, Peter N Robinson5, Martin Vingron9, Sigrid Tinschert10, Stefan Mundlos11, Mateusz Kolanczyk1.   

Abstract

Neurofibromatosis type 1 (NF1) (MIM#162200) is a relatively frequent genetic condition that predisposes to tumor formation. The main types of tumors occurring in NF1 patients are cutaneous and subcutaneous neurofibromas, plexiform neurofibromas, optic pathway gliomas, and malignant peripheral nerve sheath tumors. To search for somatic mutations in cutaneous (dermal) neurofibromas, whole-exome sequencing (WES) was performed on seven spatially separated tumors and two reference tissues (blood and unaffected skin) from a single NF1 patient. Validation of WES findings was done using routine Sanger sequencing or Sequenom IPlex SNP genotyping. Exome sequencing confirmed the existence of a known familial splice-site mutation NM_000267.3:c.3113+1G>A in exon 23 of NF1 gene (HGMD ID CS951480) in blood, unaffected skin, and all tumor samples. In five out of seven analyzed tumors, we additionally detected second-hit mutations in the NF1 gene. Four of them were novel and one was previously observed. Each mutation was distinct, demonstrating the independent origin of each tumor. Only in two of seven tumors we detected an additional somatic mutation that was not associated with NF1. Our study demonstrated that somatic mutations of NF1 are likely the main drivers of cutaneous tumor formation. The study provides evidence for the rareness of single base pair level alterations in the exomes of benign NF1 cutaneous tumors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25293717      PMCID: PMC4795057          DOI: 10.1038/ejhg.2014.210

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  19 in total

1.  MutationTaster evaluates disease-causing potential of sequence alterations.

Authors:  Jana Marie Schwarz; Christian Rödelsperger; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2010-08       Impact factor: 28.547

2.  Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.

Authors:  Lu Q Le; Tracey Shipman; Dennis K Burns; Luis F Parada
Journal:  Cell Stem Cell       Date:  2009-05-08       Impact factor: 24.633

3.  International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis.

Authors:  Rosalie E Ferner; David H Gutmann
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

Review 4.  Cancer genome landscapes.

Authors:  Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

5.  Osteopoikilosis and multiple exostoses caused by novel mutations in LEMD3 and EXT1 genes respectively--coincidence within one family.

Authors:  Sevjidmaa Baasanjav; Aleksander Jamsheer; Mateusz Kolanczyk; Denise Horn; Tomasz Latos; Katrin Hoffmann; Anna Latos-Bielenska; Stefan Mundlos
Journal:  BMC Med Genet       Date:  2010-07-09       Impact factor: 2.103

6.  Influence of hormones and hormone metabolites on the growth of Schwann cells derived from embryonic stem cells and on tumor cell lines expressing variable levels of neurofibromin.

Authors:  Therese M Roth; Poornapriya Ramamurthy; David Muir; Margaret R Wallace; Yuan Zhu; Lou Chang; Kate F Barald
Journal:  Dev Dyn       Date:  2008-02       Impact factor: 3.780

7.  Molecular dissection of isolated disease features in mosaic neurofibromatosis type 1.

Authors:  Ophélia Maertens; Sofie De Schepper; Jo Vandesompele; Hilde Brems; Ine Heyns; Sandra Janssens; Frank Speleman; Eric Legius; Ludwine Messiaen
Journal:  Am J Hum Genet       Date:  2007-06-20       Impact factor: 11.025

8.  Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity.

Authors:  M Livia Bajenaru; M Rosario Hernandez; Arie Perry; Yuan Zhu; Luis F Parada; Joel R Garbow; David H Gutmann
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

Review 9.  How does the Schwann cell lineage form tumors in NF1?

Authors:  Steven L Carroll; Nancy Ratner
Journal:  Glia       Date:  2008-11-01       Impact factor: 8.073

10.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

View more
  9 in total

1.  Computational insights of K1444N substitution in GAP-related domain of NF1 gene associated with neurofibromatosis type 1 disease: a molecular modeling and dynamics approach.

Authors:  Ashish Kumar Agrahari; Meghana Muskan; C George Priya Doss; R Siva; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2018-05-27       Impact factor: 3.584

2.  Immortalization of human normal and NF1 neurofibroma Schwann cells.

Authors:  Hua Li; Lung-Ji Chang; Debbie R Neubauer; David F Muir; Margaret R Wallace
Journal:  Lab Invest       Date:  2016-09-12       Impact factor: 5.662

3.  NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation.

Authors:  Yanan Yu; Kwangmin Choi; Jianqiang Wu; Paul R Andreassen; Phillip J Dexheimer; Mehdi Keddache; Hilde Brems; Robert J Spinner; Jose A Cancelas; Lisa J Martin; Margaret R Wallace; Eric Legius; Kristine S Vogel; Nancy Ratner
Journal:  Acta Neuropathol       Date:  2019-10-29       Impact factor: 17.088

4.  Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development.

Authors:  Krinio Giannikou; Izabela A Malinowska; Trevor J Pugh; Rachel Yan; Yuen-Yi Tseng; Coyin Oh; Jaegil Kim; Magdalena E Tyburczy; Yvonne Chekaluk; Yang Liu; Nicola Alesi; Geraldine A Finlay; Chin-Lee Wu; Sabina Signoretti; Matthew Meyerson; Gad Getz; Jesse S Boehm; Elizabeth P Henske; David J Kwiatkowski
Journal:  PLoS Genet       Date:  2016-08-05       Impact factor: 5.917

5.  Whole Exome Sequencing of Growing and Non-Growing Cutaneous Neurofibromas from a Single Patient with Neurofibromatosis Type 1.

Authors:  Daniel L Faden; Saurabh Asthana; Tarik Tihan; Joseph DeRisi; Michel Kliot
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

6.  MEK inhibitors enhance therapeutic response towards ATRA in NF1 associated malignant peripheral nerve sheath tumors (MPNST) in-vitro.

Authors:  Susan Fischer-Huchzermeyer; Anna Dombrowski; Gordon Wilke; Verena Stahn; Anna Streubel; Victor Felix Mautner; Anja Harder
Journal:  PLoS One       Date:  2017-11-13       Impact factor: 3.240

7.  Clinical characteristics and spectrum of NF1 mutations in 12 unrelated Chinese families with neurofibromatosis type 1.

Authors:  Bin Mao; Siyu Chen; Xin Chen; Xiumei Yu; Xiaojia Zhai; Tao Yang; Lulu Li; Zheng Wang; Xiuli Zhao; Xue Zhang
Journal:  BMC Med Genet       Date:  2018-06-18       Impact factor: 2.103

Review 8.  Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms.

Authors:  Jody F Longo; Shannon M Weber; Brittany P Turner-Ivey; Steven L Carroll
Journal:  Adv Anat Pathol       Date:  2018-09       Impact factor: 4.571

Review 9.  Cutaneous neurofibromas in the genomics era: current understanding and open questions.

Authors:  Robert J Allaway; Sara J C Gosline; Salvatore La Rosa; Pamela Knight; Annette Bakker; Justin Guinney; Lu Q Le
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.